ABSTRACT
INTRODUCTION: In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS-CoV-2 viral replication, but questions remained as to in-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. METHODS: We conducted a translational proof of concept randomized, double blind placebo controlled, dose response and parallel group study of IV efficacy in RT-polymerase chain reaction proven COVID 19 positive patients. Sixty-two patients were randomized to three treatment groups. (A) IV 6 mg regime, (B) IV 12 mg regime (given Q84 h for 2 weeks) (C, control) Lopinavir/Ritonavir. All groups plus standard of Care. RESULTS: The Days to COVID negativity (DTN) was significantly and dose dependently reduced by IV (P = 0.0066). The DTN for Control were, = 9.1+/-5.2, for A 6.0 +/- 2.9 and for B 4.6 +/-3.2. Two way repeated measures ANOVA of ranked COVID 19 +/- scores at 0, 84, 168 and252h showed a significant IV treatment effect (P = 0.035) and time effect (P < 0.0001). IV also tended to increase SPO2% compared to controls, P = 0.073, 95% CI-0.39 to 2.59 and increased platelet count compared to C (P = 0.037) 95%CI 5.55-162.55 × 103/ml. The platelet count increase was inversely correlated to DTN (r = -0.52, P = 0.005). No SAE was reported. CONCLUSIONS: 12mg IV regime given twice a week may have superior efficacy over 6mg IV given twice a week, and certainly over the non IV arm of the study. IV should be considered for use in clinical management of SARS-COV2, and may find applications in prophylaxis in high risk areas.
Subject(s)
COVID-19 , Ivermectin , Double-Blind Method , Humans , Nigeria , Oxygen Saturation , RNA, Viral , SARS-CoV-2 , Treatment OutcomeABSTRACT
The first epidemic of Ebola haemorrhagic disease in West Africa is the largest and longest Ebola epidemic till date, where the outbreak notably involved three countries with distant spread to other countries. It has caused significant mortality, with reported case fatality rates of up to 70%. Data and relevant information were extracted from the review of majorly relevant publications/papers about the Ebola epidemic in West Africa and other previous outbreaks of Ebola virus (EBOV). As of 2016, with the epidemic under control, the World Health Organization has warned that flare-ups of the disease are likely to continue for some time as recently occurred in Sierra Leone and the on-going in Guinea. As this may not be the last outbreak of Ebola virus disease (EVD) in West Africa, there is a need to focus on diagnostic and research capacity required to curtail EVD with adequate measures for emergency preparedness and policies for innovative treatment strategies.
Subject(s)
Hemorrhagic Fever, Ebola/epidemiology , Africa, Western/epidemiology , Ebolavirus , Guinea/epidemiology , Humans , NigeriaABSTRACT
BACKGROUND: Among the countries highly endemic for viral hepatitis, Nigeria is found. Information on how triple infected persons (HIV, HBV, and HCV) fare on HAART in the country is lacking. Laboratory based investigation was carried out to assess the virological and immunological parameters of HIV-1 infected patients co-infected with Hepatitis B and C, accessing care at the Nigerian Institute of Medical Research. It was a case controlled study. OBJECTIVES: The study aimed to compare the laboratory data of HIV-HBV-HCV patients seen between 2006 and 2009 with HIV-1 monoinfected patients in the same period, on HAART according to the national guideline and followed up for 12 months. METHODS: Detection of Hepatitis B surface Antigen (HBsAg) and Hepatitis C Virus Antibody (HCVAb) were assayed using ELISA techniques (Bio Rad and DIA PRO respectively). The CD4 and HIV viral load were determined using the Cyflow Counter/Kits (Partec) and the Amplicor HIV-1 Monitor Test V1.5 (Roche) techniques respectively. RESULTS: Forty-one (0.4%) of the 10,214 HIV-1 patients seen during the period were co-infected with both HBV and HCV. Over the 12 month-period, median HIV-1 viral load and CD4 count reduced and increased respectively (12,205-200 RNA copies/mL; 210-430 cells/mL from baseline - 12th month), and for the HIV-1 monoinfected patients (36,794-200 RNA copies/mL [p=0.5485] and 206-347 cells/mL [p=0.7703] from baseline - 12th month). CONCLUSION: There seems to be no significant influence of hepatitis B and C in HIV infection on HAART judging by the CD4 and viral load profiles which were similar in the two groups.
Subject(s)
Anti-HIV Agents , HIV Infections , HIV-1 , Hepatitis B, Chronic , Hepatitis C, Chronic , Adult , Anti-HIV Agents/immunology , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/methods , Antiretroviral Therapy, Highly Active/statistics & numerical data , CD4 Lymphocyte Count/methods , Case-Control Studies , Coinfection , Drug Monitoring , Female , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/immunology , HIV Infections/virology , HIV-1/drug effects , HIV-1/immunology , Hepatitis B Surface Antigens/blood , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/immunology , Hepatitis C Antibodies/blood , Hepatitis C, Chronic/epidemiology , Hepatitis C, Chronic/immunology , Humans , Male , Monitoring, Immunologic , Nigeria/epidemiology , Treatment Outcome , Viral Load/drug effects , Viral Load/methodsABSTRACT
BACKGROUND: There has been so many difficulties encountered in the diagnosis of HIV infection in infants < 18 months of age born to HIV-infected mother. In these infants, definitive diagnosis can only be carried out by antigen based techniques which are expensive and not widely available in developing countries. OBJECTIVE: To generate information on the rate of mother to child transmission in Nigeria and to compare the efficacies of both the HIV-1 RNA and HIV-1 DNA PCR techniques in the diagnosis of this infections in infants. METHOD: Ninety (90) whole blood samples were obtained from 45 HIV positive mothers and 45 infants born to these mothers from the Department of Obstetrics and Gynaecology, Lagos State University Teaching Hospital (LASUTH), Ikeja, Lagos. The presence of HIV was determined using the Amplicor HIV-1 DNA test and an in-house RNA PCR method. RESULTS: All the infants were HIV antibody positive, however, only 5 infants were positive by HIV-1 DNA PCR, indicating an 11% rate of transmission from HIV positive mothers. Among the 5 infants positive by the DNA PCR, only 4 were positive for the in-house RNA PCR. CONCLUSION: The 11% transmission rate recorded in this study was similar to that from mothers' who had Nevirapine ART interventions and both the HIV-1 DNA test and the in-house RNA PCR tests were sensitive and specific in the diagnosis of infection in infants, depending on the level/ state of HIV infection in infants.
Subject(s)
DNA, Viral/blood , HIV Infections/diagnosis , HIV Seropositivity/diagnosis , HIV-1/genetics , Polymerase Chain Reaction/methods , RNA, Viral/blood , Adolescent , Adult , DNA, Viral/genetics , HIV Infections/epidemiology , HIV Infections/transmission , HIV Seropositivity/epidemiology , HIV-1/immunology , Hospitals, Teaching , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical , Male , Mothers , Nigeria/epidemiology , Predictive Value of Tests , Prospective Studies , RNA, Viral/genetics , Sensitivity and Specificity , Viral Load , Young AdultABSTRACT
Definitive diagnosis of HIV infection in infants < 18 months of age who were born to HIV-infected mothers is still posing some difficulty in Nigeria and other developing countries. Within this age definitive diagnosis can only be carried out by antigen based techniques which are indeed not available in these developing countries. This has resulted in the absence of authoritative data on the rate of mother-to-child transmission in these countries. Nigeria inclusive. The present pilot study was therefore carried out to generate some information on the rate of mother to child transmission in Nigeria using the PCR technique. Plasma samples were obtained from 68 children of both sexes less than 18 months of age and who were born to HIV infected mothers. The samples were collected from two pediatric departments. in Lagos and in Benin. The presence of HIV 1 RNA in each of the samples. was determined using the Amplicor Monitor V 1.5 technique (Roche Diagnostics). Data showed that HIV-1 RNA was detected in 15 of the 68 samples tested. This gave an HIV-1 RNA detection rate of 22%. Among women who had some intervention, the rate of transmission of infection was 11% while the rate among those without intervention was 30%. The 22% transmission rate recorded in this study is close to the range of 25 to 35% that has been reported in several developed and a few developing countries. A multicenter nationwide study will still be needed to determine the national mother to child transmission rate in Nigeria.